國家衛生研究院 NHRI:Item 3990099045/3006
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 909885      在线人数 : 814
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/3006


    题名: Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients
    作者: Liu, JM;Chen, LT;Chao, Y;Li, AFY;Wu, CW;Liu, TS;Shiah, HS;Chang, JY;Chen, CT;Wu, HW;Lin, WC;Lan, C;Whang-Peng, J
    贡献者: National Institute of Cancer Research;Division of Biotechnology and Pharmaceutical Research
    摘要: Purpose: A phase 11 and pharmacokinetic study was designed to assess the efficacy and toxicity profile of an epidophyllotoxin analogue, GL331, in previously treated Chinese gastric cancer patients, with concurrent pharmacokinetic evaluation of the drug's metabolism. Material and methods: GL331 was given at 200 mg/m(2) as a daily 3-h infusion for 5 days every 4 weeks. Results: Enrolled in the study were 15 patients. One patient died from neutropenic sepsis before evaluation, one patient did not receive the full dose for reasons unrelated to GL331, nine patients had progressive disease with a median survival of 80 days, and five had stable disease with a median survival of 240 days. Grade 3 and 4 myelosuppression occurred in 10 of the 15 patients, with one death from neutropenic sepsis. This patient's peak GL331 concentration was 16.8 mug/ml,which was high compared to the mean peak drug concentration of 6 +/- 4.1 mug/ml. The mean systemic GL331 clearance was 12.1 +/- 7.2 l/h per m(2), much lower than 23.3 +/- 8.2 l/h per m(2) found in the phase I trial. Topoisomerase IIalpha was determined by immunohistochemistry and overexpression was detected in 3 of 11 specimens. Conclusions: GL331 was ineffective at this dose and schedule in this group of patients in spite of adequate blood levels of the drug.
    关键词: Oncology;Pharmacology & Pharmacy
    日期: 2002-05
    關聯: Cancer Chemotherapy and Pharmacology. 2002 May;49(5):425-428.
    Link to: http://dx.doi.org/10.1007/s00280-002-0429-3
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0344-5704&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000176113700011
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0036232644
    显示于类别:[彭汪嘉康(1996-2007)] 期刊論文
    [陳炯東] 期刊論文
    [劉敏(1996-2007)] 期刊論文
    [夏和雄(1996-2012)] 期刊論文
    [張俊彥] 期刊論文
    [陳立宗] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    000176113700011.pdf75KbAdobe PDF727检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈